Breaking News Instant updates and real-time market news.

MNK

Mallinckrodt

$13.74

-1.16 (-7.79%)

, ESRX

Express Scripts

$69.72

-0.1 (-0.14%)

11:36
04/12/18
04/12
11:36
04/12/18
11:36

Mallinckrodt, Express Scripts accused of scheme in whistleblower suit, BI says

A former Mallinckrodt (MNK) associate director claims in a whistleblower lawsuit that the company and a mail order pharmacy owned by Express Scripts (ESRX), Accredo Pharmacy, schemed "to misrepresent the actual clinical data concerning Acthar in order to alleviate the reimbursement hurdle by government payors to improperly increase Acthar sales," according to Business Insider, citing a court filing regarding the lawsuit. Mallinckrodt told Business Insider in a statement: "The company vehemently disagrees with the allegations made in the complaint and intends to vigorously defend itself in this matter." Reference Link

MNK

Mallinckrodt

$13.74

-1.16 (-7.79%)

ESRX

Express Scripts

$69.72

-0.1 (-0.14%)

  • 28

    Apr

  • 02

    May

  • 03

    May

  • 08

    May

  • 18

    May

  • 21

    May

  • 12

    Jun

  • 22

    Aug

MNK Mallinckrodt
$13.74

-1.16 (-7.79%)

02/02/18
LEHM
02/02/18
DOWNGRADE
Target $20
LEHM
Underweight
Mallinckrodt downgraded to Underweight from Equal Weight at Barclays
Barclays analyst Douglas Tsao downgraded Mallinckrodt to Underweight and cut his price target for the shares to $20 from $23. The acquisition of Sucampo (SCMP) does not address ongoing concern over Acthar and reduces the company's strategic options by raising leverage to 4.5 times, Tsao tells investors in a research note. Reimbursement pressure for Acthar could intensify, and, while not imminent, the franchise could face competition, the analyst adds.
03/16/18
WELS
03/16/18
NO CHANGE
Target $17.5
WELS
Market Perform
Mallinckrodt price target lowered to $17.50 from $22 at Wells Fargo
Wells Fargo analyst David Maris lowered his price target for Mallinckrodt to $17.50 and keeps a Market Perform rating on the name. Management did not provide directional guidance for Acthar in 2019, which is concerning, Maris tells investors in a research note. Further, Mallinckrodt's 3%-6% sales growth guidance for 2018, which implies little to no organic growth, suggests Acthar is not the company's only product facing a challenging outlook, Maris adds.
04/11/18
RHCO
04/11/18
INITIATION
Target $15
RHCO
Hold
Mallinckrodt initiated with a Hold at SunTrust
SunTrust analyst John Boris initiated Mallinckrodt with a Hold and $15 price target.
04/12/18
04/12/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Mallinckrodt (MNK) initiated with a Hold at SunTrust. 2. Hershey (HSY) initiated with a Neutral at Piper Jaffray. 3. Autoliv (ALV) initiated with a Hold at Cross Research. 4. Leap Therapeutics (LPTX) initiated with a Buy at H.C. Wainwright. 5. Monolithic Power (MPWR) initiated with a Strong Buy at Raymond James. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
ESRX Express Scripts
$69.72

-0.1 (-0.14%)

03/12/18
LEER
03/12/18
NO CHANGE
LEER
Diplomat Pharmacy may be next takeover target, says Leerink
Leerink analyst David Larsen believes Diplomat Pharmacy (DPLO) could be the next takeover target following last week's buyout of Express Scripts (ESRX). A managed care plan or large pharmacy chain may find Diplomat's portfolio compelling, Larsen told investors earlier in a research note. He believes the rally post Cigna's (CI) acquisition of Express Scripts reflects a higher likelihood of a takeover, but that "significant upside" potential remains in Diplomat shares.
03/13/18
BERN
03/13/18
INITIATION
Target $194
BERN
Market Perform
Cigna initiated with a Market Perform at Bernstein
Bernstein analyst Lance Wilkes initiated Cigna (CI) with a Market Perform rating and $195 price target following Cigna's announcement that it will buy Express Scripts (ESRX) for $67B. Wilkes views the deal as a bet that change comes more slowly to healthcare, and that financial returns from this deal will fund future strategic acquisitions for Cigna. In a research note to investors, Wilkes said he believes disruption is coming more quickly, in PBM and pharmacy and in the shift to value, and is "skeptical" of this move by Cigna. The analyst expects earnings growth to slow for Cigna driven by its employer focus, lack of scale and already best in class margins, and added that he has a "negative" outlook for Express Scripts, expecting declining gross margins as they lose Anthem (ANTM) and client pricing pressure as focus increases on drug costs.
03/15/18
DBAB
03/15/18
NO CHANGE
Target $236
DBAB
Buy
Cigna shares look oversold with or without deal, says Deutsche Bank
Cigna (CI) shares are down 26% from the January $226 high and 14% since the Express Scripts (ESRX) deal was announced on March 8, Deutsche Bank analyst Chris Rigg tells investors in a research note. The analyst estimates pro forma 2021 earnings per share of $21.18 for Cigna and Express Scripts. As such, he sees "ample conservatism" in management's 2021 EPS target range of $20-$21. With or without the deal, Cigna shares look oversold, Rigg contends. He keeps a Buy rating on Cigna with a $236 price target.
04/02/18
LEER
04/02/18
NO CHANGE
LEER
Possible Humana/Walmart deal transformational for U.S. seniors market, says Leerink
Leerink analyst Ana Gupte sees the possible Humana (HUM)-Walmart (WMT) deal as transformational for the U.S. Seniors market and estimates the deal value at close to $50B. The analyst also believes the deal helps Humana compete more effectively with UnitedHealth (UNH)/Optum and Aetna (AET)-CVS (CVS), while Walmart can also compete with Amazon (AMZN) that is eroding sales and likely eyeing an entry into the Prescription Rx market. Gupte expects the anti-trust scrutiny of three deals Aetna-CVS, Cigna (CI)-Express Scripts (ESRX) and Humana-Walmart by the DOJ will be more challenged under simultaneous review by the DOJ, though Walmart and Humana have the least anti-competitive issues. Humana-Walmart could catalyze a counter-offer for Cigna from Walgreens Boots Alliance (WBA) or even Amazon, or re-invigorate Walgreens-AmerisourceBergen (ABC) talks, she contends.

TODAY'S FREE FLY STORIES

PEP

PepsiCo

$114.99

0.01 (0.01%)

, SODA

SodaStream

$142.36

12.47 (9.60%)

12:08
08/20/18
08/20
12:08
08/20/18
12:08
General news
Fly Intel: Wall Street's top stories at midday »

Stocks opened higher…

PEP

PepsiCo

$114.99

0.01 (0.01%)

SODA

SodaStream

$142.36

12.47 (9.60%)

TSLA

Tesla

$302.31

-3.02 (-0.99%)

CBPO

China Biologic

$102.02

9.96 (10.82%)

NKE

Nike

$82.20

2.47 (3.10%)

LCI

Lannett

$5.58

-7.925 (-58.70%)

INFY

Infosys

$20.40

-0.685 (-3.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

  • 28

    Aug

  • 12

    Sep

  • 02

    Oct

  • 29

    Oct

12:05
08/20/18
08/20
12:05
08/20/18
12:05
General news
Fed's Bostic said the economy doesn't need as much stimulus as it did before »

Fed's Bostic said…

AVNW

Aviat Networks

$16.20

(0.00%)

12:04
08/20/18
08/20
12:04
08/20/18
12:04
Hot Stocks
Aviat Networks introduces online selling with new Aviat store »

Aviat Networks announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CFBK

Central Federal

$2.52

(0.00%)

12:03
08/20/18
08/20
12:03
08/20/18
12:03
Hot Stocks
Central Federal announces 1-for-5.5 reverse stock split »

Central Federal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TAHO

Tahoe Resources

$3.84

0.06 (1.59%)

12:03
08/20/18
08/20
12:03
08/20/18
12:03
Hot Stocks
Tahoe Resources terminates approx. 200 additional Minera San Rafael employees »

Tahoe Resources regrets…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BE

Bloom Energy

$22.66

0.44 (1.98%)

12:01
08/20/18
08/20
12:01
08/20/18
12:01
Hot Stocks
Street Fight: Analysts split on Bloom Energy after IPO »

Several Wall Street…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRK

Comstock Resources

$8.26

-0.46 (-5.28%)

12:00
08/20/18
08/20
12:00
08/20/18
12:00
Hot Stocks
Comstock Resources falls -5.1% »

Comstock Resources is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBP

Installed Building Products

$46.80

-2.55 (-5.17%)

12:00
08/20/18
08/20
12:00
08/20/18
12:00
Hot Stocks
Installed Building Products falls -5.3% »

Installed Building…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

  • 21

    Aug

  • 06

    Nov

LCI

Lannett

$5.55

-7.95 (-58.89%)

12:00
08/20/18
08/20
12:00
08/20/18
12:00
Hot Stocks
Lannett falls -58.7% »

Lannett is down -58.7%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

  • 28

    Aug

CATM

Cardtronics

$37.25

0.08 (0.22%)

12:00
08/20/18
08/20
12:00
08/20/18
12:00
Options
Second day of call buying in Cardtronics »

Second day of call buying…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATV

Acorn International

$22.00

3.14 (16.65%)

12:00
08/20/18
08/20
12:00
08/20/18
12:00
Hot Stocks
Acorn International rises 8.7% »

Acorn International is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRX

Amneal Pharmaceuticals

$23.96

2.43 (11.29%)

12:00
08/20/18
08/20
12:00
08/20/18
12:00
Hot Stocks
Amneal Pharmaceuticals rises 11.5% »

Amneal Pharmaceuticals is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

  • 12

    Sep

CMCM

Cheetah Mobile

$10.85

1.75 (19.23%)

12:00
08/20/18
08/20
12:00
08/20/18
12:00
Hot Stocks
Cheetah Mobile rises 19.5% »

Cheetah Mobile is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

PCG

PG&E

$45.05

-0.195 (-0.43%)

, EIX

Edison International

$69.44

-0.42 (-0.60%)

11:59
08/20/18
08/20
11:59
08/20/18
11:59
Periodicals
California's Dodd says securitization of PG&E liability mulled, Bloomberg says »

California Senator Bill…

PCG

PG&E

$45.05

-0.195 (-0.43%)

EIX

Edison International

$69.44

-0.42 (-0.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

IMTE

Integrated Media Technology

$12.20

0.2 (1.67%)

11:58
08/20/18
08/20
11:58
08/20/18
11:58
Hot Stocks
Integrated Media unit enters distribution agreement with Ai Holdings »

Integrated Media…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSFT

Microsoft

$106.76

-0.82 (-0.76%)

11:57
08/20/18
08/20
11:57
08/20/18
11:57
Hot Stocks
Skype's end-to-end encrypted Private Conversations now available for all users »

Microsoft's Skype…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 12

    Sep

TSLA

Tesla

$302.49

-2.84 (-0.93%)

11:55
08/20/18
08/20
11:55
08/20/18
11:55
Recommendations
Tesla analyst commentary  »

Tesla may be wise to try…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

TSLA

Tesla

$302.35

-2.98 (-0.98%)

11:52
08/20/18
08/20
11:52
08/20/18
11:52
Periodicals
Tesla's lawyers believe SEC 'under pressure' to expdite probe, Gasparino tweets »

FBN's Charles…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

PX

Praxair

$157.81

1.86 (1.19%)

, LNEGY

Linde

$0.00

(0.00%)

11:51
08/20/18
08/20
11:51
08/20/18
11:51
Hot Stocks
EU approves proposed merger between Linde, Praxair »

The European Commission…

PX

Praxair

$157.81

1.86 (1.19%)

LNEGY

Linde

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$285.40

0.38 (0.13%)

11:50
08/20/18
08/20
11:50
08/20/18
11:50
Options
Continued interest in end of year call spreads in SPDR 500 Trust options »

Continued interest in end…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:50
08/20/18
08/20
11:50
08/20/18
11:50
General news
Treasury's $96 B 3- and 6-month bill sale was ok »

Treasury's $96 B 3-…

XLU

Utilities SPDR

$54.43

-0.07 (-0.13%)

11:40
08/20/18
08/20
11:40
08/20/18
11:40
Options
Opening call write in SPDR Utility ETF »

Opening call write in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:36
08/20/18
08/20
11:36
08/20/18
11:36
General news
3-Month Bill Auction Total Amount data reported »

3-Month Bill Auction…

11:36
08/20/18
08/20
11:36
08/20/18
11:36
General news
6-Month Bill Auction Total Amount data reported »

6-Month Bill Auction…

IMNP

Immune Pharmaceuticals

$0.00

(0.00%)

11:36
08/20/18
08/20
11:36
08/20/18
11:36
Hot Stocks
Immune Pharmaceuticals granted Orphan Drug Designation for bertilimumab »

Immune Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.